Americas · Regional markets · Financial Post
Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 2026
For Trade and Medical Media Only CAMBRIDGE, England — Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO®…
Read the full article on Financial Post Sign in to saveMarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (financialpost.com)


